Cataract Surgery: NTC Toward a New Paradigm in post -CARE
The Italian Pharmaceutical Company NTC Present at the Escrs Congress – European Society of Cataract and Refractive Surgeons- in Vienna The Leader7 Protocol, One of the Largest European-Wide Clinical Trials in Ophthalmology in the ’ Last Decade.
“In Recent Decades, Strong Resistance Has Developed to Old-Generation Antibiotics Used in Ophthalmology, Endangening Their Effectiveness in the Proper Treatment of Patients. Ophthalmology Needs to Invest in New Clinical Evidence to Developive Antibiotic Treatments and Prophylaxis in the post -Estuing Setting of Cataract Surgery, While Offering Its Contribution in the Global Fight Against Antibiotic Resistance ” Says Francesco Bandello, Full Professor of Ophthalmology at the Vita-Salute University, San Raffaele Hospital in Milan and Coordinator of the Leader7 Study.
Leader7 is an International, Multicenter, Randomized Clinical Trial
Leader7 is an International, Multicenter, Randomized, Blinded, Parallel-Group Clinical Trial Enrolling 800 Patients at Nearly 80 Centers in 4 European Countries (Germany, Italy, Russia, Spain). The Study Compares in Solution and Fixed-Bingination Eye Drops of Levofloxacin 0.5% and dexamethasone 0.1%, Administered for 7 days and followed by the Administration of Dexamethasone 0.1% Alone for an additional 7 Days, with a suspense and fixed-blombation Eye Drops of tobramycin and dexamethasone, Administered for 14 days, for the Treatment of inflammation and prevention of infection associated with cataract surgery in adults.
“The Fixed Combination of Levofloxacin and Dexamethasone in Eye Drops Aims To Represent An innovative Therapeutic Solution for Use in the post -Estuing of Cataract Surgery ” Says Federico Bertocchi, Chief Scientific Officer of NTC – Design, The Leader7 Study is designed for the first time to demonstrate that a one-week antibiotic prophylaxis is equivalent to a two-week. It is the first product to combine a quinolone antibiotic with a steroidal anti-inflammotory in Europe ” in an Eye Drop;.
The ’ Use of a Fixed Combination in Ophthalmology is becoming Increationly Established
The ’ Use of a Fixed Combination in Ophthalmology is Increationly Establishing Itself as the Standard of Care, with the ’ Goal of Providing The Best Control of Inflammation and Pain, Coupled with adquate and Poten Antibiotic Protection.
“ Following The Example of the World Health Organization ’ S Projects aimed at Combatting Antibiotic Resistance, NTC is engaged in a variety of clinical program aimed at rationalizing the ’ Use of antibiotic therapy in Ophthalmology ” Says Riccardo Cabucicchio, CEO of NTC “ We are strongly Committed to Reducing the Development of Antibiotic Resistance by Offering New Clinical Evidence in Ophthalmology. This is the Fight that All Pharmaceutical Companies Should Be Doing These Days “.
Among More Than 30 Research and Development Projects Currently Underway, Mainly in Ophthalmology, Leader7 Represents in Key Study Amag Ntc Investments.